Your browser doesn't support javascript.
loading
Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report.
Sawayama, Saki; Murakami, Ryusuke; Aki, Megumi; Kawaguchi, Yusuke; Takao, Yumi; Nonogaki, Hirofumi; Goto, Tomoyuki; Yamauchi, Chikako.
Affiliation
  • Sawayama S; Department of Obstetrics and Gynecology, Shiga General Hospital, Moriyama, Shiga, Japan.
  • Murakami R; Department of Obstetrics and Gynecology, Shiga General Hospital, Moriyama, Shiga, Japan.
  • Aki M; Department of Obstetrics and Gynecology, Shiga General Hospital, Moriyama, Shiga, Japan.
  • Kawaguchi Y; Department of Obstetrics and Gynecology, Shiga General Hospital, Moriyama, Shiga, Japan.
  • Takao Y; Department of Obstetrics and Gynecology, Shiga General Hospital, Moriyama, Shiga, Japan.
  • Nonogaki H; Department of Obstetrics and Gynecology, Shiga General Hospital, Moriyama, Shiga, Japan.
  • Goto T; Department of Gynecology, Minamikusatsu Health Examination Centre, Kusatsu, Shiga, Japan.
  • Yamauchi C; Department of Gastroenterology and Hepatology, Shiga General Hospital, Moriyama, Shiga, Japan.
Gynecol Oncol Rep ; 41: 100993, 2022 Jun.
Article de En | MEDLINE | ID: mdl-35586703
ABSTRACT
•We reported the use of pazopanib in the treatment of recurrent uterine carcinosarcoma with FGFR1 amplification.•The expert tumor board recommended pazopanib for off-label use based on genetic mutations found in cancer gene panels.•Pazopanib, a multi-tyrosine kinase inhibitor, was effective against recurrent uterine sarcoma with FGFR1 amplification.•Pazopanib maintained the patient's quality of life for a certain period.
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Aspects: Patient_preference Langue: En Journal: Gynecol Oncol Rep Année: 2022 Type de document: Article Pays d'affiliation: Japon
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Aspects: Patient_preference Langue: En Journal: Gynecol Oncol Rep Année: 2022 Type de document: Article Pays d'affiliation: Japon